Casi Pharmaceuticals took part in drug developer Juventas' $14.5m series A-plus round after licensing the latter's Car T-cell drug candidate for haematological malignancies last month.

China-based biopharmaceuticals developer Juventas completed an RMB100m ($14.5m) series A-plus round yesterday led by drug manufacturer Casi Pharmaceuticals, according to China Money Network. Venture capital firms Dalton Venture and Panacea Venture both contributed to the round. Founded in June 2018 and previously called Juventas Cell Therapy, the company develops immunotherapeutic drugs while also providing R&D,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.